Eyebright Medical(688050) Zheng Quan Zhi Xing·2025-05-29 12:29Core Viewpoint - The independent financial advisor report indicates that the conditions for the fourth vesting period of the initial grant and the third vesting period of the reserved grant under the 2021 restricted stock incentive plan of Aibo Medical have been met [1][12]. Summary by Sections Company Overview - Aibo Medical, officially known as Aibo Nord (Beijing) Medical Technology Co., Ltd., is involved in a restricted stock incentive plan aimed at motivating key personnel [1]. Incentive Plan Details - The initial grant's fourth vesting period is defined as the period from the first trading day after 48 months from the grant date to the last trading day within 60 months from the grant date, which is set from June 16, 2021, to June 15, 2026 [8]. - The reserved grant's third vesting period is defined as the period from the first trading day after 36 months from the reserved grant date to the last trading day within 48 months from the reserved grant date, set from March 31, 2025, to March 27, 2026 [11]. Performance Conditions - For the initial grant, the company must achieve an average compound growth rate of adjusted net profit of 35% for the year 2024, with the actual growth rate reported at 44.87%, thus meeting the performance target [10]. - The performance assessment for individual participants is categorized into four levels: Excellent, Good, Qualified, and Unqualified, determining the actual number of shares vested based on company and individual performance [10][11]. Approval Process - The incentive plan underwent several approval stages, including board meetings and shareholder meetings, with necessary independent opinions and verification from the supervisory board [6][7][8]. Independent Advisor's Opinion - The independent financial advisor confirms that the conditions for the vesting of the restricted stock have been fulfilled and that the relevant matters have received the necessary authorizations and approvals [12].